10/12/01

"Express Mai Date of Deposit:

abel No.: EL918916579US

1.1.11.01

BEK Seq





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re-application of: Susan M. Freier

Antisense Modulation of insulin-like growth factor binding protein 5 Expression

BOX SEQUENCE Assistant Commissioner for Patents Washington DC 10131



PATENT APPLICATION TRANSMITTAL LETTER

Transmitted herewith for filing, please find the following:

- · The specification of the above-referenced patent application;
- An executed Declaration or Oath and Power of Attorney;
- · An Assignment of the invention to Isis Pharmaceuticals Inc. with recordation cover sheet (PTO Form PTO 1505) and 340.00 cover fee;
- · Statement to Support Filing and Submission of DNA Amino Acid Sequences in Accordance with 37 CFR § § 1.821 through 1.825;
- Sequence listing in computer readable form in accordance with 37 C.F.R. § 1.821(e);
- An Information Disclosure Statement with references; and
- Applicant claims small entity status pursuant to 37 CFR § 1.27.

The filing fee has been calculated as shown below:

For:	No. Filed	No. Extra	Rate	Fee
BASE FEE				\$370.00
Total Claims	20 - 20 =	0	X \$9=	\$0
Indep. Claims	2 - 3 =	0	x\$40=	so
TOTAL				\$ 370.00

The Commissioner is hereby authorized to charge the following fees to Deposit Account No. 500252:

- the amount of \$410.00 for the above listed fees;
- payment of the fill wind feed and disteriorith this organization or creat any
- anytaititi nalitilina teed negairei onder et twellile includina teed tarquedentat. d Postara Plainte and
- any additional patent application processing feed under 30 MMR 1.10 and under 30 MMR.

Triplicate copies of this transmittal are enclosed.

Date: Cotober 8, 2001

I amochec (Monto

Example to the Artist

March 6 Hr Serve

DOCKET NO.:RTS-0253

"Express Mail" Label No.: EL918916579US

Date of Deposit: |C|C|C|

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Susan M. Freier

Serial No.: not yet assigned Filing Date: herewith

Title: Antisense Modulation of insulin-like growth factor binding protein 5 Expression

BOX SEQUENCE Assistant Commissioner for Patents Washington, D.C., 20231

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821 THROUGH 1.825

I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same.

Date: Cctober 8, 2001

Respectfully submitted,

Laurel Spear Bernstein Registration No. 37,280 Isis Pharmaceuticals, Inc.

Please address all correspondence to:

Licata & Tyrrell, P.C. 66 East Main Street Marlton NJ 09053 (***) %1 151°